

INVION GENERAL MEETING: RESULTS OF MEETING

Melbourne, Australia, 30 January 2019: Invion Limited (ASX:IVX) is pleased to provide the results of its General Meeting.

All resolutions were passed, determined by Poll.

The results provided in the attached document are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

About Invion

Invion is a clinical-stage life-sciences company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers. Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of Photosoft™. The appointment has been made by technology licensor, The Cho Group, a Hong Kong based group that has funded and successfully commercialised a number of unique and advanced technologies. Via an R&D services agreement between the two entities, the research and clinical trials of Photosoft™ are funded by The Cho Group. Invion has an alliance with leading Australian medical research institute, Hudson Institute of Medical Research, for the Photosoft™ research program.

Investor enquiries

Managing Director & CEO, Dr Greg Collier

T: +61 3 9081 6005

E: investor@inviongroup.com

EXTRAORDINARY GENERAL MEETING
Wednesday, 30 January, 2019

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
	Votes <i>For</i>	Votes <i>Against</i>	Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>
1 CAPITAL REDUCTION AND DISTRIBUTION OF CHRONIC AIRWAY THERAPEUTICS LIMITED SHARES (CAT SHARES)	3,777,603,257	10,465,215	6,877,172	2,754,271	3,820,065,234 99.73%	10,465,215 0.27%	2,754,271
2 ADOPTION OF EMPLOYEE SHARE OPTION PLAN	114,922,263	21,725,780	6,877,172	5,975,748	132,412,679 85.91%	21,725,780 14.09%	5,975,748
3 ELECTION OF MR ALAN YAMASHITA AS A DIRECTOR	3,777,697,312	9,970,960	6,926,061	3,105,582	3,820,208,178 99.74%	9,970,960 0.26%	3,105,582
4 APPROVAL TO ISSUE OPTIONS TO MR THIAN CHEW	113,729,341	22,943,007	6,902,172	5,926,443	131,244,757 85.12%	22,943,007 14.88%	5,926,443
5 APPROVAL TO ISSUE OPTIONS TO DR GREG COLLIER	113,983,779	22,713,569	6,877,172	5,926,443	131,474,195 85.27%	22,713,569 14.73%	5,926,443
6 APPROVAL TO ISSUE OPTIONS TO DR JAMES CAMPBELL	113,385,881	23,286,467	6,902,172	5,926,443	130,901,297 84.90%	23,286,467 15.10%	5,926,443
7 APPROVAL TO ISSUE OPTIONS TO DR MITCHELL GLASS	113,833,778	22,713,569	7,042,072	5,911,544	131,489,094 85.27%	22,713,569 14.73%	5,911,544
8 APPROVAL TO ISSUE OPTIONS TO MR ALAN YAMASHITA	113,725,604	22,999,244	6,869,672	5,906,443	131,208,520 85.09%	22,999,244 14.91%	5,906,443

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item

EXTRAORDINARY GENERAL MEETING
Wednesday, 30 January, 2019

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
	Votes <i>For</i>	Votes <i>Against</i>	Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>
9 ISSUE OF SHORT TERM INCENTIVES TO DR GREG COLLIER	3,206,489,618	22,588,686	13,199,274	6,017,844	3,230,302,136 99.31%	22,588,686 0.69%	6,017,844

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item